Mission Bio

/ 6000 Shoreline Court, Suite 104

94080 South San Francisco

US

Mission Bio

Foundation date

2012

Sector

#Pharma

Subsector

Mission Bio unlocks the ground truth of cancer through response, relapse, and remission with its Tapestri Platform, powered by single-cell multi-omics. As the first and only to analyze genotype and phenotype simultaneously in single cells, the Tapestri Platform can help unravel the inherent complexity of cancer. Discover how Tapestri enables accurate characterization of your cell and gene therapy candidates for safer and more effective therapeutic strategies. We partner with pharma and biopharma companies across advanced therapy development programs to implement proven single-cell multi-omics capabilities into discovery, translational, and clinical research efforts. Learn more about our Pharma Assay Development services.

Upcoming events

Latest news

  • SeptiCyte® RAPID receives 510(k) clearance by US FDA

    Wednesday December 1st 2021

  • QbD and Inovigate launch Health to Market, a contract commercialization organization in life sciences

    Wednesday December 1st 2021

  • Dimitrios Mantzilas joins Precirix as Chief Technology Officer

    Wednesday December 1st 2021